InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
74.04
(
1.55%
)
Bitcoin
68,760.84
(
-0.79%
)
Post# of 9706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Singhania

Send PM Follow Ignore
Followers 3
Posts 551
Boards Moderated 0
Alias Born 07/16/2014

Singhania

Re: None

Friday, 06/07/2024 9:28:22 AM

Friday, June 07, 2024 9:28:22 AM

Post# of 9706
$OCX Last week, Oncocyte announced positive data results for its flagship diagnostic product, VitaGraft™.

In a phase 2 double-blind, placebo-controlled study (NCT05021484), VitaGraft Kidney was used to monitor graft injury associated with the investigational drug felzartamab, a fully human CD38 monoclonal antibody, aimed at treating antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.

VitaGraft Kidney assesses the health of grafts by measuring the amount of donor-derived DNA in the blood of transplant patients, serving as a crucial biomarker.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up